discussed elsewhere (Woodruff 1965) it seems unlikely that this continued survival is due to the development of specific immunological tolerance, and it seems reasonable to attribute the phenomenon to some form of graft adaptation, in the sense in which this term was originally defined (Woodruff 1959) . In man there has been an understandable reluctance to stop immunosuppressive drugs completely in patients with long-surviving kidney transplants but the dosage has been reduced to almost homeeopathic proportions.
The risk of infection appears to be much smaller with immunosuppressive drugs than with whole body irradiation. Gastroduodenal hemorrhage and/or perforation may occur in patients receiving large doses of steroids, and severe muscular wasting may be a problem in patients given large doses of azathioprine.
Antilymphocytic Serum It has been shown that homografts may survive for long periods despite a high degree of donorrecipient incompatibility in rats (Woodruff & Anderson 1963 , mice (Monaco et al. 1965 , Levey & Medawar 1966 and dogs (Abaza et al. 1966 ) treated with heterospecific antilymphocyte serum (ALS) . Administration of the serum may be delayed until after the transplantation and may abolish pre-existing immunity to tissue of the same inbred donor strain (Levey & Medawar 1966) . It is still an open question whether there is a critical time after which administration of ALS can be stopped without prejudice to the continued survival of a homograft when no other method of immunosuppression is used. This would appear to be so, however, when administration of ALS is combined with thymectomy (Jeejeebhoy 1965 , Monaco et al. 1966 .
Our experiments with ALS in dogs suggest that the risk of infection, especially of viral infection, is considerable, and this risk extends to organisms against which the treated animal has been actively immunized. Research is urgently required to discover how this risk can best be reduced.
It was thought likely that prolonged administration of ALS would result in damage to the kidneys, liver and possibly other organs by complexes of proteins of the serum and antibodies to these proteins produced by the treated animal. So far this does not appear to have happened, possibly because antigen overloading has inhibited antibody production, though we do not as yet have evidence to support this conjecture.
We have prepared some horse-anti-human ALS and tested it in vitro with human lymphocytes, but have not yet used it clinically. It seems possible, however, that it may prove to be a valuable agent in transplant recipients and also in patients suffering from severe autoimmune disease.
Dr M F Kahn", Dr M Bedoiseau and Professor S de Size (Clinique Rhumatologique de l'Hopital Lariboisiere, Centre Viggo-Petersen, Paris, France)
Immunosuppressive Drugs in the Management of Malignant and Severe Rheumatoid Arthritis An autoimmune mechanism has been postulated in rheumatoid arthritis (Christian & Kunkel 1963) and several attempts to treat possible autoimmune disorders by lowering the level of immunological Since then, several reports have been published dealing with immunosuppressive treatment of rheumatoid arthritis (Table 1) , as well as of systemic lupus erythematosus and related disorders. The main reasons for using immunosuppressive drugs in rheumatoid arthritis are summarized in Table 2 . Barnet & Vaughan (1961) , and Kahn & de Seze (1962) were the first to report data obtained in patients treated with d-penicillamine with the aim of lowering the titre of rheumatoid factor in the serum. Jaffe (1962) showed the effect of this compound used orally or intra-articularly and he (1964) and de Seze et al. (1965) reported satisfactory results in malignant rheumatoid arthritis.
In 1963 we started a preliminary trial of chlorambucil (Leukeran) in rheumatoid arthritis and the results of this trial are reported here.
Material and Methods
Forty patients with classical active rheumatoid arthritis were selected out of 412 cases of rheumatoid arthritis seen by us from 1963 to 1965. The criteria used for selection were as follows: (1) Patients whose disease was not controlled despite full conservative management, including one month hospital bed rest, gold (in a series of doses, each 1 2 g, unless side-effects were troublesome), antimalarial drugs and prednisone in a dose of 11 +6 mg/day. In some patients we did not want to give more than 15 mg/day prednisone; in others, the low dosage of daily prednisone could not be increased because of side-effects, including psychosis, peptic ulcer, osteoporosis and cushingoid syndrome. We included in this selection three cases of histologically proven necrotizing arteritis complicating rheumatoid arthritis with high titre rheumatoid factor, and two cases of associated lymphocytic leukWmia and rheumatoid arthritis. Details of the 40 patients are summarized in Table 3. (2) Patients who would attend at least once a week for several months. (3) Only patients aged over 40, unless life appeared to be threatened.
Chlorambucil was given in a dose of 0-2 mg/ kg/day until a satisfactory result was obtained or until leucopenia of less than 2,000 white cells/ c.mm, or thrombocytopenia of less than 100,000 platelets/c.mm was achieved. Clinical evaluation was performed at least once a week and an overall estimation made before and after therapy. The criteria used were modifications of the Lansbury objective index. Differential blood counts were performed once or twice a week, and the blood sedimentation rate, Rose-Waaler test, quantitative latex fixation test, LE cell test and the Mantoux skin test (using 10 TU) were carried out before and after therapy.
Every week, following the clinical evaluation, corticosteroid therapy was adjusted to the exact level suitable to suppress the activity of the disease. The average dose of chlorambucil was 1,020± 540 mg given in 14 ± 8 weeks.
Results were evaluated under the following headings:
Excellent: Total remission, no treatment other than aspirin 1 g or less. Good: Total remission with suppression of at least 50% or more of the initial corticosteroid maintenance dose. Questionable: Objective improvement of the previous activity of the disease but not possible to lower the corticosteroid daily maintenance dosage by more than 40% of the initial dosage; or total remission but not possible to lower the corticosteroid dosage at all. Poor: Every other result including subjective improvement.
Results
The overall results were as follows: Excellent 11; good 13; questionable 1 1; poor 5.
Since the therapy was not started at the same time for all patients the follow-up period ranges between three and thirty months. Our first 12 patients (de Seze et al. 1965 ) have now been followed up for thirty months. The results are: Excellent 3; good 5; questionable 3; and poor 1.
These results do not differ from those seen in the whole group. Two patients with initial good results relapsed within one year; they received subsequent courses of eight weeks of chlorambucil and both responded again. One patient who had shown a poor result died of a cerebral thrombosis three months after the end of the treatment and her death is the only one in our group of 40 patients.
The 3 patients with necrotizing arteritis all had excellent results as far as this complication was concerned. In all 3, skin lesions and neuropathy failed to increase and then healed within three to six months. The effect on the underlying rheumatoid arthritis was excellent in one, good in one and questionable in the third. The 2 patients having both rheumatoid arthritis and lymphocytic leukamia underwent a remission of the blood disease; an excellent result being obtained in the rheumatoid arthritis in one case, and a good result in the other.
These results were not related to the total amount of chlorambucil given, nor to the degree of lymphopenia induced. There was a slight correlation with the duration of disease and the initial severity of the rheumatoid arthritis, results being somewhat better in cases of less than six years' duration and initially severe.
The biological data are reported in Table 4 . The decrease in rheumatoid factor, when observed, occurred within two to eight months. In a control group of 40 seropositive patients with rheumatoid arthritis seen at the same timre, the variations in titre of the rheumatoid factor in the serum were not significant. Leucopenia was observed in almost all our cases and, as expected from the use of this drug in blood diseases, particularly affected lymphocytes. The decrease in circulating lymphocytes 
Complications ofTreatment
We have had no deaths in our series owing to the treatment, and this compares favourably with the reports of others (see Table 1 ). The toxicity of chlorambucil for bone marrow, and specifically for granulocytes and thrombocytes, seems to be somewhat lower and slower than that of 6-mercaptopurine or azathioprine. Side-effects are summarized in Table 5 .
Conchlsions
As far as can be concluded from our series (which did not include a control group) treatment of malignant or severe rheumatoid arthritis with chlorambucil gives satisfactory results in some cases. In the specially selected group of severe cases which we studied some results were questionable or poor, but even established treatments with gold, antimalarials, &c., are not always effective and failure to obtain improvement in every case does not mean that immunosuppressive treatment of rheumatoid arthritis is ineffective. If this treatment is effective the way it works remains obscure. We have no data to relate possible immunosuppression and the clinical results, and the immunological abnormality in rheumatoid arthritis is not yet fully accepted as causative. O'Brien and his co-workers (1962), using methotrexate, obtained satisfactory results in psoriatic arthritis, in which no immunological disturbance has so far been shown. Intra-articular thiotepa, although disappointing in our hands, has been claimed (Flatt 1962) to diminish synovial inflammation by acting directly on cellular components of the inflammatory reaction. A similar situation might result from systemic administration of so-called immunosuppressive drugs in rheumatoid arthritis.
The absence of severe side-effects observed with chlorambucil does not allow us to conclude that the drug is innocuous. We know little about the delayed effects, and one must keep in mind the occurrence of late leukwmia following X-ray therapy in ankylosing spondylitis or benzol intoxication. Morever, like every cytolytic agent, chlorambucil can cause fcetal abnormalities and therefore must be avoided in pregnancy. Our conclusions may be summarized as follows:
(1) Immunosuppressive agents (in our hands, chlorambucil) seem to be effective in the management of malignant and severe rheumatoid arthritis, when the disease escapes control by current therapy.
(2) The course of this therapy must be carefully controlled and should be carried out only in a well-equipped hospital.
(3) Further studies are needed to determine the range and impact of its effectiveness.
